Clinical trial · no report yet · Phase 3
StrateGIST 3
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
- NCT07218926 ↗
- Recruiting
- GlaxoSmithKline
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 12 | |
| Podcasts | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Gastrointestinal Neoplasms
- Interventions
- IDRX-42; Sunitinib
- Arms
- IDRX-42 (GSK6042981) · Experimental
- Sunitinib · Active comparator
- Enrollment
- 450 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor
- GlaxoSmithKline
- Start
- Dec 3, 2025
- Primary completion
- May 30, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT07218926 · updated Oct 5, 2026